Omeprazole: What Clinical Studies Show

Omeprazole was the first proton pump inhibitor (PPI) to reach the market and remains one of the most prescribed medicines in the UK. It is used for heartburn, reflux, stomach ulcers and to protect the stomach from anti-inflammatory painkillers — a common concern for athletes who rely on ibuprofen or naproxen. Its long history means a large body of clinical research, including some well-publicised safety debates. Our editorial team summarises what the studies actually show.

How omeprazole works

Omeprazole blocks the hydrogen-potassium ATPase, the "proton pump" in the parietal cells of the stomach lining that secretes acid. It is a prodrug: it is activated in the acidic environment of the parietal cell and then binds irreversibly to the pump. Acid secretion resumes only when new pumps are made, which is why a single daily dose provides prolonged suppression.

It works best when taken 30–60 minutes before a meal, ideally breakfast, because pumps are most active after eating. Full effect develops over several days of regular use, which is why PPIs are less suitable than antacids for instant relief.

In the UK, omeprazole is available on prescription in 10, 20 and 40 mg strengths, and 20 mg tablets for short-term heartburn relief can be bought from pharmacies. Licensed adult doses for most indications are 10–40 mg once daily, as set out in the summary of product characteristics.

Omeprazole is a racemic mixture; its S-isomer is marketed separately as esomeprazole. Head-to-head comparisons show broadly similar clinical outcomes at equivalent doses.

Evidence in ulcers and reflux disease

The clinical case for omeprazole was established in the late 1980s and 1990s. Randomised trials showed faster and more complete healing of duodenal and gastric ulcers than with H2-receptor antagonists such as ranitidine. In erosive oesophagitis, omeprazole healed a markedly higher proportion of patients than H2 blockers.

PPIs also became a cornerstone of Helicobacter pylori eradication. Triple therapy combining a PPI with two antibiotics achieved eradication rates far higher than previous regimens and transformed ulcer care by preventing recurrence. NICE guidance continues to recommend PPI-based regimens.

For gastro-oesophageal reflux disease (GORD), omeprazole is effective for both healing and maintenance. NICE advises using the lowest effective dose and reviewing long-term use at least annually, stepping down or stopping where possible.

Protection against NSAID damage

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit protective prostaglandins in the stomach and can cause ulcers and bleeding. Two landmark trials published in 1998 in the New England Journal of Medicine addressed this directly.

The ASTRONAUT trial compared omeprazole with ranitidine in patients needing continuous NSAIDs and found omeprazole more effective at healing and preventing ulcers. The OMNIUM trial compared omeprazole with misoprostol and found similar healing with better tolerability for omeprazole, plus lower relapse rates during maintenance.

For athletes, the lesson is nuanced. Routine NSAID use for training aches is not recommended, as it may impair tissue healing and increase kidney and gut risks during endurance events. When NSAIDs are medically necessary in people at higher risk of GI bleeding, a doctor may co-prescribe a PPI.

PPIs protect the stomach and duodenum but not the small intestine, where NSAIDs can also cause damage. They do not offer protection against NSAID-related kidney injury.

Interactions and the clopidogrel debate

Omeprazole inhibits the liver enzyme CYP2C19, which converts the antiplatelet drug clopidogrel into its active form. Laboratory studies showed reduced clopidogrel activity when the two were combined, leading the MHRA and other regulators to advise avoiding the combination.

The COGENT trial, published in 2010, randomised patients on clopidogrel and aspirin to omeprazole or placebo. Omeprazole reduced GI bleeding without a statistically significant increase in cardiovascular events, although the trial ended early and was not powered to exclude a modest effect. Regulatory advice to prefer alternatives such as lansoprazole or pantoprazole with clopidogrel has largely remained.

Other notable interactions include:

• reduced absorption of drugs that need acid, such as some antifungals, iron tablets and certain HIV medicines;
• increased levels of methotrexate at high doses;
• altered levels of some anti-epileptics and of tacrolimus.

A pharmacist can check any combination quickly and should be consulted before starting omeprazole alongside other regular medicines.

Long-term safety: what the evidence says

Observational studies have linked long-term PPI use with a range of problems, including fractures, community-acquired pneumonia, Clostridioides difficile infection, low magnesium, vitamin B12 deficiency, chronic kidney disease and dementia. These findings generated considerable media attention.

The largest randomised evidence comes from the COMPASS trial, in which over 17,000 patients were randomised to pantoprazole or placebo for about three years. Apart from a possible increase in enteric infections, pantoprazole was not associated with the feared harms. Because COMPASS studied a different PPI, extrapolation to omeprazole is reasonable but not perfect.

Well-established risks include hypomagnesaemia with prolonged use, which can cause muscle cramps, tremor and arrhythmias — symptoms relevant to athletes. The MHRA recommends considering magnesium measurement in long-term users. Acute interstitial nephritis is rare but recognised.

Stopping omeprazole after long use can cause rebound acid hypersecretion for a few weeks. Tapering under medical guidance makes this easier.

Editorial team's conclusions

Omeprazole is one of the best-studied medicines in gastroenterology. Trials consistently show it heals ulcers and oesophagitis, supports H. pylori eradication and protects against NSAID-related ulcers. Long-term safety signals from observational research are mostly reassuring in randomised data, but low magnesium, infections and drug interactions are real. Use the lowest effective dose for the shortest necessary time, and review regularly with a doctor.

Related topics you might find useful include NSAIDs and the risks of using painkillers before endurance events, gastrointestinal problems in runners, and magnesium deficiency in athletes.

References

1. Yeomans ND, Tulassay Z, Juhász L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338(11):719–726.
2. Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338(11):727–734.
3. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–1917.
4. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682–691.
5. National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184). London: NICE; 2014.
6. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762.